TCGA-E2-A152-01A-11R-A12D-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 71
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- TGF_BETA_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.380
- ANDROGEN_RESPONSE+0.340
- HYPOXIA+0.330
- PROTEIN_SECRETION+0.330
- COAGULATION+0.320
- GLYCOLYSIS+0.310
- MTORC1_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.380
- INTERFERON_ALPHA_RESPONSE-0.330
- MYC_TARGETS_V1-0.280
- DNA_REPAIR-0.230
- E2F_TARGETS-0.230
- ESTROGEN_RESPONSE_EARLY-0.200
- INTERFERON_GAMMA_RESPONSE-0.180
- UV_RESPONSE_UP-0.120
- BILE_ACID_METABOLISM-0.110
- FATTY_ACID_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.818 |
| 2 | TCGA-AC-A23E-01A-11R-A157-07 | — | A | 0.807 |
| 3 | TCGA-A1-A0SM-01A-11R-A084-07 | — | C | 0.792 |
| 4 | ERR2208939 | — | — | 0.791 |
| 5 | TCGA-AQ-A0Y5-01A-11R-A14M-07 | — | C | 0.789 |
| 6 | TCGA-EW-A2FR-01A-11R-A21T-07 | — | C | 0.786 |
| 7 | TCGA-AN-A0AS-01A-11R-A00Z-07 | — | C | 0.783 |
| 8 | SRR25617869 | — | F | 0.781 |
| 9 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.778 |
| 10 | TCGA-D8-A142-01A-11R-A115-07 | — | E | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |